Does a High CEA Mean Cancer? Normal Values and Causes

Short Answer

A high CEA (carcinoembryonic antigen) does not definitely mean cancer. Smoking, liver diseases, bowel inflammation and some benign conditions also raise CEA. According to the US National Cancer Institute (NCI), tumor markers do not work well for screening. In Türkiye, bowel cancer screening is done not with CEA but with a fecal occult blood test at ages 50–70. Evaluate your result against the laboratory reference range on your report.

How does it appear on your report?

On reports, the test is written as "Carcinoembryonic antigen (CEA)" or simply "CEA". In the Turkish Ministry of Health's Test Measurement Units list, the unit for CEA is µg/L. Many reports use ng/mL; the two are numerically the same.

The "Tahlillerim" (My Tests) screen in e-Nabız (Türkiye's national health record app) shows the result together with its reference value and marks out-of-range values in color. With the chart icon, you can see your previous CEA results side by side. In follow-up, this trend matters more than a single value.

A single number or a range? For CEA, the report often shows a single upper limit such as "below 5". According to the Ministry of Health procedure, laboratories distinguish decision limits from the reference range by marking them with an asterisk (*). Read the explanation at the bottom of your report.

Method differences: According to the European Group on Tumor Markers (EGTM) 2014 guideline, different CEA tests can give different results. Therefore, in follow-up, the same laboratory and method should always be used if possible.

Normal value and reference range

Situation	Value	What does it mean?	Source
General upper limit	Above 3–5 ng/mL is considered high	The limit varies by laboratory	Hall et al., 2019
Smokers, men and older adults	Higher baseline value	Mild elevation is common	Hall et al., 2019
Above 10 ng/mL or a rising trend	More often associated with malignant causes	Detailed evaluation is needed	Hall et al., 2019
Above 20 ng/mL	Suspicious for disseminated disease	Specialist evaluation is needed	Hall et al., 2019

The reference range covers 95% of healthy people; about 1 in 20 healthy people may fall slightly outside the range. The upper limit on your own report takes precedence over the examples in this table.

What does it mean if it is high?

The causes are listed from common and harmless to serious.

1. Smoking, age and sex. According to a comprehensive 2019 review, the baseline CEA value is higher in smokers, men and older adults. In these people, a mild elevation is common and often harmless.

2. Liver and bile duct diseases. CEA is largely broken down in the liver. Therefore, liver dysfunction and bile duct obstruction can raise CEA. Cirrhosis and hepatitis are also known causes.

3. Inflammatory and benign conditions. Infections, stomach ulcers, inflammatory bowel disease, pancreatitis, hypothyroidism and benign breast diseases can increase CEA. EGTM 2014 also warns that some benign diseases can raise CEA.

4. Cancers. CEA is most associated with colorectal cancer. It can also rise in other cancers such as stomach, pancreatic, lung, breast and medullary thyroid cancer. In one study, the probability of finding colorectal cancer was 4.6% in those with high CEA and 1.3% in those with normal CEA.

The reverse is also important: many people with colorectal cancer have a normal CEA. The authors of the review found no evidence supporting the use of CEA as a screening tool. Therefore, a normal CEA does not replace further investigation if you have complaints.

What is CEA really used for? The National Academy of Clinical Biochemistry (NACB) 2008 guideline recommends CEA in colorectal cancer for three purposes. These are determining prognosis, postoperative surveillance and monitoring treatment in advanced disease. According to EGTM 2014, in stage II–III colorectal cancer that is a candidate for additional treatment, CEA is measured every 2–3 months for the first 3 years. After that, it can be checked about every 6 months up to the 5th year.

When read together

• Mildly high CEA + smoking + no other findings: According to the approach in the review, if CEA is below 10 ng/mL, further tests may not be needed. Smoking is stopped and CEA and clinical evaluation are repeated after 3 months.
• High CEA + high liver enzymes or bilirubin: A liver or bile duct cause comes to the fore.
• High CEA + anemia or iron deficiency: Bowel evaluation comes into consideration together with a complete blood count and iron tests.
• Positive fecal occult blood: Colonoscopy is needed whatever the CEA result.
• Rising CEA after colorectal cancer surgery: According to EGTM 2014, further tests are done after the rise is confirmed with a second sample.
• Normal CEA + rectal bleeding or unexplained weight loss: A normal CEA does not rule out cancer; see a physician.

Preparing for the test

• Smoking: If you smoke, tell your physician; the interpretation is made accordingly.
• Biotin: According to the Ministry of Health's 2024 guide, high-dose biotin can make immunological tests falsely low or falsely high depending on the method. If you use a supplement, tell the laboratory.
• Same laboratory: If possible, have follow-up measurements done at the same laboratory with the same method.
• No decision on a single measurement: An unexpected rise is first confirmed with a second sample.
• Worry about the result: Do not compare the result with sample values on the internet before evaluating it with your physician.

Which doctor, which test?

• First step: Family physician or internal medicine; repeat CEA, complete blood count, iron tests, liver and kidney tests.
• Gastroenterology: If fecal occult blood is positive, or if there is anemia, a change in bowel habits or rectal bleeding.
• Colonoscopy: Recommended for everyone with a positive fecal occult blood test.
• Medical oncology: People with a history of cancer whose CEA rises during surveillance.
• Additional markers: Depending on the clinical situation, CA 125 or calcitonin may be requested.
• If you are between 50 and 70: Ask your family physician or a KETEM for free fecal occult blood screening.

In Türkiye

• National screening program: The Turkish Ministry of Health's General Directorate of Public Health (HSGM) screens women and men aged 50–70 for colorectal cancer every 2 years with a fecal occult blood test. The US recommendation of age 45 is not Türkiye's program.
• Other screenings: The HSGM program includes mammography every 2 years at ages 40–69 for breast cancer, and an HPV test every 5 years at ages 30–65 for cervical cancer. CEA is not used in any program.
• KETEM: Cancer Early Diagnosis, Screening and Education Centers (KETEM) and family physicians perform these screenings free of charge.
• Data from Türkiye: Pre-transplant data of 381 patients who underwent liver transplantation in Malatya were examined. It was shown that tumor markers, including CEA, can rise in end-stage liver disease. The elevation varied according to the cause and severity of the disease.
• Units: In the national unit list, CEA is reported in µg/L.

When should you seek emergency care?

• If there is heavy rectal bleeding, black tarry stools, or dizziness together with bleeding, call 112 (the emergency number in Türkiye).
• If there is abdominal swelling, vomiting and inability to pass gas or stool, call 112; it may be a bowel obstruction.
• If yellowing of the eyes and skin occurs together with fever or severe abdominal pain, go to the emergency department the same day.
• If the laboratory has called you about a critical value, see your physician or go to the emergency department the same day.

Related lab tests

• Lab Test Guide: all tests
• High CA 125: cyst or cancer?
• High CA 15-3: it is not a breast cancer screening test
• When should liver enzymes be taken seriously?
• How to read a complete blood count
• CRP, ESR and procalcitonin: inflammation tests

What changed? (October 2026)

• The HSGM national cancer screening standards were used as the basis: for colorectal screening, ages 50–70, a fecal occult blood test every 2 years.
• EGTM 2014 surveillance recommendations and NCI's tumor marker information reviewed in December 2023 were added.

Sources

• Turkish Ministry of Health, General Directorate of Public Health (T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, HSGM). Kanser Taramaları (national screening standards). Current version. https://hsgm.saglik.gov.tr/tr/kanser-taramalari (accessed October 2, 2026)
• Turkish Ministry of Health (T.C. Sağlık Bakanlığı). e-Nabız Kullanım Kılavuzu V2.1. 2025. https://enabiz.gov.tr/document/User_Manual.pdf (accessed October 2, 2026)
• Turkish Ministry of Health, SHGM (T.C. Sağlık Bakanlığı SHGM). Test Ölçüm Birimleri, Versiyon 2. 15.09.2021. https://dosyamerkez.saglik.gov.tr/Eklenti/41467/0/test-olcum-birimleri-versiyon-2-pdfpdf.pdf (accessed October 2, 2026)
• Turkish Ministry of Health, SHGM (T.C. Sağlık Bakanlığı SHGM). Tıbbi Biyokimya Toplam Test Süreci Rehberi, Publication No 1287. May 2024. https://dosyamerkez.saglik.gov.tr/Eklenti/48692/0/tibbi-biyokimya-toplam-test-sureci-rehberipdf.pdf (accessed October 2, 2026)
• Baskıran DY, Sarıgöz T, Baskıran A, Yılmaz S. The Significance of Serum Tumor Markers CEA, CA 19-9, CA 125, CA 15-3, and AFP in Patients Scheduled for Orthotopic Liver Transplantation. J Gastrointest Cancer. 2023;54:442-446. https://doi.org/10.1007/s12029-021-00798-5 (accessed October 2, 2026)
• Sturgeon CM et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11-79. https://doi.org/10.1373/clinchem.2008.105601 (accessed October 2, 2026)
• Duffy MJ et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European Group on Tumor Markers 2014 guidelines update. Int J Cancer. 2014;134:2513-2522. https://doi.org/10.1002/ijc.28384 (accessed October 2, 2026)
• Hall C et al. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol. 2019;35:294-305. https://doi.org/10.3393/ac.2019.11.13 (accessed October 2, 2026)
• National Cancer Institute (NCI). Tumor Markers (reviewed December 7, 2023). https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet (accessed October 2, 2026)
• Clinical and Laboratory Standards Institute (CLSI). EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. 2010, reaffirmed in 2020. https://clsi.org/shop/standards/ep28/ (accessed October 2, 2026)